BackScancell Holdings plc Overview

Scancell Holdings plc EBIT

Scancell Holdings plc's EBIT is $-29M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$8.48M
↓ 90.39% YoY

As of Apr 30, 2026

Annual EBIT (TTM)

-$29.32M
↓ 86.54% YoY

Trailing 12 months ending Apr 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Scancell Holdings plc (SCNLF) FAQ

The latest EBIT for SCNLF is $-29M as of April 2026. That compares with $-16M in the prior-year period — down 86.5% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Scancell Holdings plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, SCNLF's EBIT moved from $-16M to $-29M — a 86.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Scancell Holdings plc's operating scale or balance-sheet position.

Against Healthcare companies, SCNLF currently prints $-29M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Scancell Holdings plc's growth, margins, and balance sheet.

A EBIT figure of $-29M for SCNLF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting SCNLF's EBIT ($-29M), review year-over-year change from $-16M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers